RemeGen’s $4.2 billion licensing deal falls flat with investors
The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
Recent Articles
RELATED ARTICLES
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
